共 68 条
[1]
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]
Mitra A(2015)EMT, CTCs and CSCs in tumor relapse and drug-resistance Oncotarget 6 10697-10711
[3]
Mishra L(2022)Advances with androgen deprivation therapy for prostate cancer Expert Opin Pharmacother 23 1015-1033
[4]
Li S(2020)Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States Clin Genitourin Cancer 18 284-294
[5]
Yu EM(2022)Comparison of systemic treatments for metastatic castration-resistant prostate cancer after docetaxel failure: a systematic review and network meta-analysis Front Pharmacol 15 71-71
[6]
Aragon-Ching JB(2015)Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp Cancer Cell Int 7 1513-464
[7]
George DJ(2018)Recent trends in the management of advanced prostate cancer F1000Res 234 116781-784
[8]
Chen JR(2019)Cancer stem cell (CSC) resistance drivers Life Sci 12 445-659
[9]
Alfarouk KO(2015)Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update Nat Rev Clin Oncol 162 773-7424
[10]
Ritch C(2011)Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein Br J Pharmacol 138 645-1063